Literature DB >> 6401631

Free fraction of valproic acid: in vitro time-dependent increase and correlation with free fatty acid concentration in human plasma and serum.

F Albani, R Riva, G Procaccianti, A Baruzzi, E Perucca.   

Abstract

The effect of sample incubation and storage on the protein binding of the antiepileptic drug valproic acid (VPA) and on the concentration of free fatty acids (FFA) was investigated in serum and plasma collected from four normal volunteers. Both the free fraction of VPA and the concentration of FFA increased progressively with time when samples were incubated at 4 to 37 degrees C. These effects occurred to the same extent in both serum and heparinized plasma. At 4 degrees C and at room temperature, the increase in free drug fraction was relatively small (18 and 25% respectively at 24 h), whereas at 37 degrees C it was quite considerable (24% at 8 h and 40% at 24 h). At room temperature, FFA rose on average by 22% at 4 h, 34% at 8 h, and 86% at 24 h, whereas at 37 degrees C the increases at the same incubation times were 59, 90, and 160%, respectively. There was a strong positive relationship between changes in free VPA fraction and FFA content of the samples. The time-dependent changes in VPA binding capacity described in this study may lead to overestimation of the actual free concentration in vivo, especially when this is estimated by equilibrium dialysis or ultracentrifugation techniques requiring long incubation (centrifugation) times at 37 degrees C.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401631     DOI: 10.1111/j.1528-1157.1983.tb04867.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

Review 1.  Pharmacokinetic considerations in the treatment of childhood epilepsy.

Authors:  Jamie T Gilman; Michael Duchowny; Ana E Campo
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

2.  Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.

Authors:  R L Semmes; D D Shen
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

3.  Rationale for monitoring free drug levels.

Authors:  R H Levy; T A Moreland
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

4.  Differential transplacental binding of valproic acid: influence of free fatty acids.

Authors:  F Albani; R Riva; M Contin; A Baruzzi; M Altomare; G P Merlini; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

5.  Pharmacokinetics of valproic acid in the elderly.

Authors:  E Perucca; R Grimaldi; G Gatti; S Pirracchio; F Crema; G M Frigo
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

6.  Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing.

Authors:  W G Rapeport; A D Mendelow; G French; P MacPherson; E Teasdale; E Agnew; G G Thompson; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

Review 7.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

8.  In vivo plasma protein binding interaction between valproic acid and naproxen.

Authors:  R Grimaldi; S Lecchini; F Crema; E Perucca
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Oct-Dec       Impact factor: 2.441

Review 9.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

10.  SPECT in the localisation of extratemporal and temporal seizure foci.

Authors:  M R Newton; S F Berkovic; M C Austin; C C Rowe; W J McKay; P F Bladin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-07       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.